Endo International PLC (NASDAQ:ENDP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “2017 will continue to be challenging for Endo as the generics base business and the legacy branded pain franchise are expected to decline further. Shares of Endo have significantly underperformed the Medical-Drugs industry in the past one year. The company’s Generic segment is also under pressure given the challenging competitive landscape and pricing pressures. With the  company pulling off Opana ER from the market over growing concern of opioid abuse epidemic, the top-line will be further impacted. Also, the Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions. Concerns relating to pricing are expected to remain a major overhang on the shares. However, Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables.”

Several other analysts have also recently issued reports on the company. Deutsche Bank AG cut their price objective on Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Guggenheim started coverage on Endo International PLC in a research note on Saturday, June 17th. They set a “hold” rating and a $12.00 price objective on the stock. Cantor Fitzgerald started coverage on Endo International PLC in a report on Friday, June 16th. They set a “neutral” rating and a $12.00 target price for the company. BidaskClub lowered Endo International PLC from a “hold” rating to a “sell” rating in a report on Thursday, June 15th. Finally, William Blair reaffirmed a “market perform” rating on shares of Endo International PLC in a report on Wednesday, June 14th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have given a buy rating to the company’s stock. Endo International PLC currently has an average rating of “Hold” and a consensus target price of $16.63.

Endo International PLC (NASDAQ ENDP) traded up 0.80% on Tuesday, reaching $11.36. The company had a trading volume of 2,739,362 shares. The stock has a 50 day moving average of $12.19 and a 200 day moving average of $12.47. Endo International PLC has a 12 month low of $9.70 and a 12 month high of $24.93. The firm’s market capitalization is $2.53 billion.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.10 by $0.13. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the previous year, the firm posted $1.08 earnings per share. The company’s revenue was up 7.7% compared to the same quarter last year. On average, analysts anticipate that Endo International PLC will post $3.57 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Endo International PLC (ENDP) to Sell” was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/11/zacks-investment-research-downgrades-endo-international-plc-endp-to-sell.html.

A number of institutional investors have recently modified their holdings of ENDP. Amalgamated Bank raised its position in shares of Endo International PLC by 2.0% in the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock worth $361,000 after buying an additional 619 shares during the last quarter. Capstone Asset Management Co. raised its position in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock worth $358,000 after buying an additional 960 shares during the last quarter. Point View Wealth Management Inc. raised its position in shares of Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock worth $128,000 after buying an additional 1,254 shares during the last quarter. Jensen Investment Management Inc. raised its position in shares of Endo International PLC by 5.8% in the first quarter. Jensen Investment Management Inc. now owns 24,660 shares of the company’s stock worth $275,000 after buying an additional 1,360 shares during the last quarter. Finally, Macquarie Group Ltd. raised its position in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the last quarter. 93.28% of the stock is owned by hedge funds and other institutional investors.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International PLC (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.